ATXA Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Crowdfunding

  • Latest Deal Amount
  • $1.03M

  • Investors
  • 5

ATXA Therapeutics General Information

Description

Developer of a clinical-stage pharma company intended for heart and lung conditions that targets human thromboxane receptor antagonists. The company's medications use a strategy to improve vasodilation and decrease the potential for vasoconstriction by inhibiting the action of the proteinoid thromboxane in cases of thrombosis, renal, prostate, and certain metastatic cancers, as well as other types of pulmonary hypertension and certain types of heart disease, enabling patients to get a proper line of treatment and cure.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • UCD Conway Institute for Biomolecular & Biomedical Research
  • University College Dublin, Belfield
  • Dublin 4
  • Ireland
+353 (01)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • UCD Conway Institute for Biomolecular & Biomedical Research
  • University College Dublin, Belfield
  • Dublin 4
  • Ireland
+353 (01)

ATXA Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ATXA Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Equity Crowdfunding 30-Oct-2025 $1.03M Completed Clinical Trials - Phase 2
10. Later Stage VC 16-May-2024 Completed Clinical Trials - Phase 2
9. Equity Crowdfunding 01-May-2024 Completed Clinical Trials - Phase 2
8. Grant 15-Jun-2022 Completed Clinical Trials - Phase 2
7. Later Stage VC 20-Jul-2020 Completed Pre-Clinical Trials
6. Later Stage VC (Series A) 01-Apr-2020 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 08-Jan-2018 Completed Pre-Clinical Trials
4. Early Stage VC 01-Sep-2016 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 01-Jul-2015 $295K $295K Completed Startup
2. Accelerator/Incubator 01-May-2015 Completed Startup
To view ATXA Therapeutics’s complete valuation and funding history, request access »

ATXA Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Convertible Preference
A Convertible
Convertible Preference 125 $0.010727 $1072.71 $1072.71 1x $1072.71 5.34%
Series A 265 $0.010727 $1072.71 $1072.71 1x $1072.71 11.32%
To view ATXA Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ATXA Therapeutics Patents

ATXA Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025242874-A1 Drug-in-capsule formulations of thromboxane receptor antagonists Pending 28-Mar-2024
US-20250302848-A1 Drug-in-capsule formulations of thromboxane receptor antagonists Pending 28-Mar-2024
WO-2025202463-A1 Drug-in-capsule formulations of thromboxane receptor antagonists Pending 28-Mar-2024
AU-2021304808-A1 Thromboxane receptor antagonist formulations Pending 07-Jul-2020
CA-3188796-A1 Thromboxane receptor antagonist formulations Pending 07-Jul-2020 A61K9/1635
To view ATXA Therapeutics’s complete patent history, request access »

ATXA Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ATXA Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
European Union Government
European Innovation Council Accelerator/Incubator Minority
Enterprise Ireland Growth/Expansion Minority
Institutional Investor Corporation Minority
NovaUCD Accelerator/Incubator Minority
To view ATXA Therapeutics’s complete investors history, request access »

ATXA Therapeutics FAQs

  • When was ATXA Therapeutics founded?

    ATXA Therapeutics was founded in 2015.

  • Where is ATXA Therapeutics headquartered?

    ATXA Therapeutics is headquartered in Dublin, Ireland.

  • What is the size of ATXA Therapeutics?

    ATXA Therapeutics has 10 total employees.

  • What industry is ATXA Therapeutics in?

    ATXA Therapeutics’s primary industry is Drug Discovery.

  • Is ATXA Therapeutics a private or public company?

    ATXA Therapeutics is a Private company.

  • What is the current valuation of ATXA Therapeutics?

    The current valuation of ATXA Therapeutics is .

  • What is ATXA Therapeutics’s current revenue?

    The current revenue for ATXA Therapeutics is .

  • How much funding has ATXA Therapeutics raised over time?

    ATXA Therapeutics has raised $19.9M.

  • Who are ATXA Therapeutics’s investors?

    European Union, European Innovation Council, Enterprise Ireland, Institutional Investor, and NovaUCD have invested in ATXA Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process